Published in AIDS Weekly, November 29th, 2004
Owings will lead the business and market development efforts for the organizations Retina Mitox products and technology in the United States and North American markets.
"The need to have a direct US operational presence is critical to the company's strategic mission in developing the Retina Mitox market for mitochondrial toxicity," said Dr. Bob van Gemen, chief executive officer of Primagen Holding BV in Amsterdam, The Netherlands. "We are very happy to have found someone who can develop these...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.